参考文献 References
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018.
[3] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[4] Wong VK, Tse SK, Lam KC, et al. Chinese medicine for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials[J]. Integr Cancer Ther, 2014, 13(1): 1-12.
[5] 姜建伟,钟晓明,章红燕,等.芍药软肝方对肺癌化疗患者肝损伤的保护作用[J].中国中医药科技,2019,26(04): 598 -600.
[6] 孙燕,张爱琴,余新民,等.芍药软肝合剂对肝癌H_(22)荷瘤小鼠的抑瘤作用及对Bax、Survivin表达的影响[J].浙江中医杂志,2013,48(11):839-841.
[7] 李骏飞,郑小蓉,姜建伟,等.基于Bax/Bcl-2-Caspase-3通路芍药软肝方抑制裸鼠肝癌生长及机制研究[J].中国现代医生,2021,59(07):38-41+45+193.
[8] Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role in development and disease[J]. Cell, 2010, 140(4): 445-449.
[9] Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and tumor suppression[J]. Endocr Relat Cancer, 2010, 17(1): F19-F36.
[10] Heo I, Joo C, Cho J, et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA[J]. Mol Cell, 2008, 32(2): 276-284.
[11] Balzeau J, Menezes MR, Cao S, Hagan JP. The LIN28/let-7 Pathway in Cancer. Front Genet. 2017 Mar 28;8:31. doi: 10.3389/fgene.2017.00031.
[12] Li G, Wakao S, Kitada M, Dezawa M. Tumor suppressor let-7 acts as a key regulator for pluripotency gene expression in Muse cells. Cell Mol Life Sci. 2024 Jan 23;81(1):54. doi: 10.1007/s00018-023-05089-9.
[13] Deshmukh SK, Srivastava SK, Zubair H, Khan MA, Singh AP, Singh S. Resistin Induces LIN28A-Mediated Let-7a Repression in Breast Cancer Cells Leading to IL-6 and STAT3 Upregulation. Cancers (Basel). 2021 Sep 7;13(18):4498.